Antidiabetic Activity of Momordica charantia Fruit Extract in Streptozotocin-Induced Diabetic Rats

Abstract

Bitter melon, the fruit of Momordica charantia, is among the most widely used traditional remedies for diabetes, and reports of its glucose-lowering effect in streptozotocin-induced diabetic rats are common. This narrative review asks what such reports can and cannot establish. It draws on published work on the chemistry and proposed mechanisms of the fruit, on how streptozotocin damages pancreatic beta cells, on the design and reporting of rodent studies, and on the small human literature, and it presents no new data and no local experiment. The fruit contains several groups of compounds, including cucurbitane triterpenoids and protein fractions, with plausible actions on glucose uptake, insulin release and hepatic glucose output, yet most proposed mechanisms rest on cell work or on single animal studies. Streptozotocin models are convenient, but the degree of beta-cell loss, the timing of confirmation, spontaneous recovery and the choice of extract all shape the outcome. Weak points of the reporting, notably small groups, unclear randomisation and blinding, undefined extracts and treating cages as independent units, limit how far a positive result can travel. A glucose-lowering effect in the rat is plausible and often reproduced in direction, but its size, its mechanism and its relevance to people remain unsettled. The review closes with the features a convincing study of a fruit extract in this model would contain.